MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2024-25)
- Udyam number
- UDYAM-HR-13-0003163
Kaansla Pharmaceuticals Private Limited - pharma in Panchkula, Haryana, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹62.11 Lakh
▲ 58% YoY
Net profit · FY 2025
₹1.58 Lakh
Net margin 2.5%
EBITDA · FY 2025
₹4.54 Lakh
EBITDA margin 7.3%
Authorised capital
₹15 Lakh
Registered with MCA
Paid-up capital
₹10 Lakh
Issued & subscribed
Company age
6 yrs
Est. 2020
Directors on board
2
As per MCA filings
Active GSTINs
1
GST registered
About Kaansla Pharmaceuticals Private Limited
Data last updated:
Kaansla Pharmaceuticals Private Limited is a private limited company based in Panchkula, Haryana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 December 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24239HR2020PTC091817. Its GSTIN is 06AAICK5232F1ZQ (Haryana).
The company has an authorised share capital of ₹15 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors Satish Verma and Monika Verma.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at House No. 698 Rai Pur Rani, Panchkula, Haryana, India – 134204.
As per the financials filed for FY 2025, the company reported a revenue of ₹62.11 Lakh, a growth of 58% compared to the previous year. For the same year it recorded a net profit of ₹1.58 Lakh (net margin 2.5%) and EBITDA of ₹4.54 Lakh (EBITDA margin 7.3%). Revenue has grown at a compounded annual rate (CAGR) of 31% over three years.
Kaansla Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-HR-13-0003163). For more details, the company can be reached via its website kaanslapharma.com.
Company details
CIN U24239HR2020PTC091817
Registration Number 091817
Incorporation Date 24 December 2020
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
MSME Classification Micro
Udyam Registration UDYAM-HR-13-0003163
Key People
Satish Verma Director Monika Verma Director Recognitions & Rankings of Kaansla Pharmaceuticals
Contact details
Kaansla Pharmaceuticals Private Limited's registered office is in Panchkula, Haryana. Its website is kaanslapharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressHouse No. 698 Rai Pur Rani, Panchkula, Haryana, India – 134204
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Kaansla Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Kaansla Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Kaansla Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Kaansla Pharmaceuticals Private Limited, buy the company report.
Financials of Kaansla Pharmaceuticals Private Limited
FY 2025 filings availableKaansla Pharmaceuticals Private Limited reported revenue of ₹62.11 Lakh (up 58% YoY) for FY 2025.
Revenue · FY 2025
₹62.11 Lakh ▲ 58%
Net profit · FY 2025
₹1.58 Lakh margin 2.5%
EBITDA · FY 2025
₹4.54 Lakh margin 7.3%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 58%
3 years · compounded
▲ 31%
EBITDA CAGR growth
1 year
▲ 59%
3 years · compounded
▲ 38%
Revenue has grown at a compounded annual rate (CAGR) of 31% over three years, including 58% growth in the latest year. EBITDA rose 59% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹4.54 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.58 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 7.3% | ||||
| Net Profit Margin | 2.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Kaansla Pharmaceuticals Private Limited, buy the company report.
Board of directors of Kaansla Pharmaceuticals Private Limited
Kaansla Pharmaceuticals has 2 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Satish Verma | Director | 24 Dec 2020 | 5 Years 10 Months | Current |
| Monika Verma | Director | 24 Dec 2020 | 5 Years 10 Months | Current |
Peer comparison
Kaansla Pharmaceuticals Private Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Nevcare Pharmaceuticals Private Limited | ₹62.24 Lakh (FY 2024) | 155.0% | Thane, Maharashtra, India | |||
| Rozer Pharmaceuticals Private Limited | ₹62.21 Lakh (FY 2025) | 22.0% | Kalyan, Maharashtra, India | |||
| Mezon Pharmaceuticals Private Limited | ₹62.12 Lakh (FY 2024) | -16.0% | Ludhiana, Punjab, India | |||
| Kaansla Pharmaceuticals Private Limitedthis company | ₹62.11 Lakh (FY 2025) | ₹1.58 Lakh | 2.5% | 58.0% | Panchkula, Haryana, India | |
| Resilio Pharmaceuticals Private Limited | ₹62.1 Lakh (FY 2024) | 10.0% | Hyderabad, Telangana, India | |||
| Meracus Pharmaceuticals Private Limited | ₹62 Lakh (FY 2024) | 31.0% | Kolkata, West Bengal, India | |||
| Altiva Pharmaceuticals (OPC) Private Limited | ₹61.74 Lakh (FY 2017) | 1156.0% | New Delhi, Delhi, India |
To see the full peer comparison of Kaansla Pharmaceuticals Private Limited, buy the company report.
Auditor
Kaansla Pharmaceuticals Private Limited is audited by KBB & CO. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| KBB & CO. | FY 2023 | 023819N |
Shareholding
The shareholding of Kaansla Pharmaceuticals Private Limited is on record for 2 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2021 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Kaansla Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Kaansla Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Kaansla Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Kaansla Pharmaceuticals Private Limited has 1 active EPFO establishment as of Apr 07, 2024.
Active EPFO establishments
1
GST
Kaansla Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 06AAICK5232F1ZQ | Haryana | Active | 14 Jan 2021 |
To see the full GST registrations and return filing status of Kaansla Pharmaceuticals Private Limited, buy the company report.
Recent activity
Kaansla Pharmaceuticals Private Limited has 2 board changes on record since 2020: 2 appointments. The latest: Monika Verma was appointed as Director on 24 Dec 2020.
AGM
Kaansla Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Kaansla Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi.
Appointed
Monika Verma was appointed as Director.
Appointed
Satish Verma was appointed as Director.
Incorporation
24 Dec 2020
Kaansla Pharmaceuticals Private Limited was registered on 24 Dec 2020 with Roc Delhi & aged 5 years 10 months as per MCA records.
Frequently asked questions
Kaansla Pharmaceuticals is an active private limited company based in Panchkula, Haryana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 December 2020 (6+ years old) and is registered under CIN U24239HR2020PTC091817.
Kaansla Pharmaceuticals has 2 current directors:
- Satish Verma - Director
- Monika Verma - Director
The latest financial statements of Kaansla Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2021 are in the company report.
The GSTIN of Kaansla Pharmaceuticals is 06AAICK5232F1ZQ, registered in Haryana.
The CIN (Corporate Identification Number) of Kaansla Pharmaceuticals is U24239HR2020PTC091817. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Kaansla Pharmaceuticals was incorporated on 24 December 2020, making it 6+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Kaansla Pharmaceuticals by revenue are Nevcare Pharmaceuticals Private Limited, Rozer Pharmaceuticals Private Limited, Mezon Pharmaceuticals Private Limited, Resilio Pharmaceuticals Private Limited, Meracus Pharmaceuticals Private Limited and 1 more, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Monika Verma was appointed as Director on 24 Dec 2020. Satish Verma was appointed as Director on 24 Dec 2020.
Yes, Kaansla Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-HR-13-0003163).
Kaansla Pharmaceuticals can be reached through the website kaanslapharma.com. Its registered office is in Panchkula, Haryana, India.
The registered office of Kaansla Pharmaceuticals is at House No. 698 Rai Pur Rani, Panchkula, Haryana, India – 134204.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages